Compare SCWO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SCWO | MOLN |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | Switzerland |
| Employees | 27 | N/A |
| Industry | Environmental Services | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 158.9M |
| IPO Year | N/A | 2021 |
| Metric | SCWO | MOLN |
|---|---|---|
| Price | $2.86 | $4.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 45.4K | 4.1K |
| Earning Date | 04-02-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | $318.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $3.36 |
| 52 Week High | $3.55 | $5.36 |
| Indicator | SCWO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 51.34 |
| Support Level | $2.35 | $3.51 |
| Resistance Level | $3.10 | $5.33 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 74.73 | 46.82 |
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.